Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pres. Sagara Says Profit Increase Still Ways Away, Company to Invest to Enhance Pipeline: Ono
May 16, 2013
- PII Study of Terbinafine Patch for Tinea Unguium in US Shows No Significant Difference Against Placebo in Primary Endpoint: Hisamitsu
May 16, 2013
- Investigation on Ranbaxy Quality Issue Ends, Risks Eliminated: Daiichi Sankyo Pres.
May 15, 2013
- Eisai Forecasts 1st Sales Rise in 4 Years in FY2013, Business Slump to Bottom Out: Pres. Naito
May 15, 2013
- Otsuka Holdings’ Pharma Sales Up 8.8% in FY2012, Spurred by Upbeat Abilify
May 15, 2013
- Diabetes Treatment Market to Exceed 500 Billion Yen in 2017: Fuji-Keizai
May 15, 2013
- Eight Companies Initiate Voluntary Recall of Enalapril Generics Due to Deviations from Specifications
May 15, 2013
- Astellas’s FY2012 Sales Top 1 Trillion Yen; XTANDI Scores 12.2 Billion Yen in 1st Year
May 14, 2013
- Ono Sales Down 0.3% Despite New Product Sales Increase, Double-Digit Decline in Profits Due to Higher Cost to Sales Ratio
May 14, 2013
- Takeda Not to Release 3-Year Mid-Term Business Plan, Changes to Annual Business Forecast
May 14, 2013
- Eisai Operating Profit Down 26%, Fails to Meet Revised Domestic Sales Target for Aricpet
May 14, 2013
- Daiichi Sankyo FY2012 Sales Up 6.3%; Leads Way with Near Double-Digit Growth in Japan Pharma Biz
May 14, 2013
- Four Leading Wholesalers See Clear Recovery in Pharmaceutical Wholesale Business
May 14, 2013
- DSP to Increase Latuda Sales Force to 450 in North America
May 13, 2013
- Yakult Pharmaceutical Sales and Profit Down as Elplat Sales Decline
May 13, 2013
- Millennium: Anna Protopapas Becomes President, R&D Functions Integrated into Takeda
May 13, 2013
- Ethical Drug Sales Down 0.7%, OTC Drug Sales Surge 8.9% in March: Crecon Report
May 13, 2013
- Meiji Seika Pharma Leads in Percentage of Female MRs with a Ratio of 1 Female to 3 MRs: Jiho Survey
May 13, 2013
- MTPC Royalties Reach 19.5 Billion Yen from Out-Licensed Gilenya
May 10, 2013
- Shionogi Chalks Up Record Profits as US Unit Buoys Sales
May 10, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…